The new suite integrates workflows for COPD, lung nodules, and pulmonary embolism to improve patient follow-up and treatment times.
RT’s Three Key Takeaways:
- Integrated Ai Workflows: The new suite combines identification and coordination for conditions like chronic obstructive pulmonary disease and lung nodules into a single platform integrated with electronic health records.
- Reduced Treatment Times: Early data from a single-center study showed that the pulmonary embolism component of the suite reduced time to treatment from 1.75 days to 0.56 days.
- Addressing Care Gaps: The technology aims to reduce health system leakage and missed diagnoses, as current data shows up to 71% of lung nodules and 79% of incidental pulmonary embolisms do not receive appropriate follow-up.
Viz.ai announced the launch of the Viz Pulmonary Suite, an artificial intelligence-powered solution designed to streamline healthcare delivery for acute and chronic pulmonary conditions.
The platform integrates workflows for COPD, lung nodules, and pulmonary embolism (PE) into a single system that connects with electronic health records (EHR). According to a news release from Viz.ai, the suite aims to improve patient retention and outcomes by providing context-aware summaries and surfacing clinical guidelines to prevent missed diagnoses and treatment delays.
The suite includes Viz PE, which was shown in a single-center study to reduce time to treatment for high-risk patients from 1.75 days to 0.56 days, according to Viz.ai. The study also indicated a decrease in in-hospital mortality among high-risk PE patients.
“Pulmonary care breaks down not because we lack treatments, but because patients may be lost between moments of care,” said Tim Showalter, MD, chief medical officer of Viz.ai, in a news release. “Across COPD, pulmonary embolism, and lung nodules, critical findings are often identified but not acted on in time due to fragmented workflows. The Viz Pulmonary Suite brings identification, coordination, and follow-through into a single solution that is fully integrated with the EHR, helping clinicians intervene earlier and manage these patients with greater consistency.”
Fragmented care remains a significant challenge for the more than 34 million US adults living with chronic lung disease. Viz.ai reports that nearly half of COPD patients hospitalized for acute exacerbations are readmitted within 30 days, and up to 71% of clinically significant lung nodules do not receive appropriate follow-up. Additionally, up to 79% of incidental PE cases are missed on initial imaging, despite 67% of those cases being clinically significant.
“As patients move through imaging, the emergency room (ER), and acute care visits, their journey often becomes fragmented,” said Lakshman Swamy, MD, MBA, FCCP, chief pulmonologist at Monogram Health, in a news release. “Solutions like the Viz Pulmonary Suite provide clinical teams with connected Ai-enabled workflows to help identify potential patients earlier, act more efficiently, and support more consistent follow-up across the care continuum.”
Viz.ai will demonstrate the suite at ATS 2026 from May 17-19, 2026.
